Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

June 25, 2024

Study Completion Date

December 31, 2025

Conditions
Neurofibromatosis 1
Interventions
DRUG

N-Acetyl cysteine

Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).

OTHER

Placebo

Eight (8) weeks of treatment with placebo.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Children's Hospital Medical Center, Cincinnati

OTHER